FDA to expedite ev3's Pipeline

The Food & Drug Administration grants ev3 Inc. an expedited review of the pre-market approval application the company filed in May for its Pipeline cerebral aneurysm treatment.

One of Covidien plc's (NYSE:COV) pending acquisitions won some good news from the Food & Drug Administration after it granted ev3 Inc. (NSDQ:EVVV) an expedited review of its Pipeline embolization treatment for cerebral aneurysms.

Plymouth, Minn.-based ev3 said the FDA agreed to consider the pre-market approval application it filed May 18 for the device, which is designed to treat large, giant and wide-necked brain aneurysms. The federal watchdog agency granted the company an expedited review and processing of the PMA.